GlaxoSmithKline S.A.E (EGX:BIOC)
Egypt · Delayed Price · Currency is EGP 453.00
-9.00 (-1.95%)
At close: Aug 25, 2026
GlaxoSmithKline S.A.E Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,618 | 3,731 | 2,991 | 2,240 | 1,823 | 1,812 | |
Revenue Growth | 2.80% | 24.73% | 33.51% | 22.87% | 0.62% | -9.07% |
Cost of Revenue | 2,894 | 3,051 | 2,057 | 1,451 | 1,266 | 1,105 |
Gross Profit | 724.08 | 679.77 | 933.94 | 789.12 | 557.4 | 706.66 |
Selling, General & Admin | 373.15 | 449.97 | 406.75 | 366.27 | 326.91 | 409.16 |
Other Operating Expenses | 11.04 | 18.46 | 36.68 | -7.32 | 204.15 | 24.56 |
Operating Expenses | 337.64 | 463.12 | 508.07 | 340.29 | 542.07 | 464.5 |
Operating Income | 386.44 | 216.65 | 425.87 | 448.83 | 15.33 | 242.16 |
Interest Expense | -46.61 | -11.62 | -10.6 | -37.96 | -33.5 | -48.67 |
Interest & Investment Income | 27.05 | 27.05 | 78.28 | 42.15 | - | 0.26 |
Earnings From Equity Investments | 18.4 | 35.3 | 1 | -18.12 | 12.15 | -9.21 |
Currency Exchange Gain (Loss) | -176.4 | 56.97 | -147.63 | -169.75 | 34.53 | -5.39 |
Other Non Operating Income (Expenses) | 11.97 | - | - | - | - | - |
EBT Excluding Unusual Items | 220.85 | 324.34 | 346.91 | 265.15 | 28.5 | 179.13 |
Impairment of Goodwill | - | - | - | -137.65 | -101 | - |
Gain (Loss) on Sale of Assets | 0.61 | 0.48 | -2.4 | 0.17 | 5.94 | 0.24 |
Legal Settlements | 0.65 | 0.65 | -5.79 | -7.94 | 3.61 | - |
Pretax Income | 216.64 | 325.48 | 338.72 | 119.74 | -62.94 | 179.37 |
Income Tax Expense | 24.56 | 112.24 | 164.74 | 59.26 | 50.87 | 24.74 |
Earnings From Continuing Operations | 192.08 | 213.24 | 173.98 | 60.47 | -113.81 | 154.63 |
Earnings From Discontinued Operations | - | - | - | - | 849.21 | - |
Net Income to Company | 192.08 | 213.24 | 173.98 | 60.47 | 735.4 | 154.63 |
Minority Interest in Earnings | -0.02 | -0.01 | -0 | -0.02 | -0.02 | 0.01 |
Net Income | 192.06 | 213.23 | 173.98 | 60.46 | 735.38 | 154.64 |
Preferred Dividends & Other Adjustments | -2.12 | - | - | - | - | - |
Net Income to Common | 194.18 | 213.23 | 173.98 | 60.46 | 735.38 | 154.64 |
Net Income Growth | 38.72% | 22.56% | 187.78% | -91.78% | 375.56% | 449.70% |
Shares Outstanding (Basic) | 84 | 84 | 84 | 84 | 84 | 84 |
Shares Outstanding (Diluted) | 84 | 84 | 84 | 84 | 84 | 84 |
Shares Change | -0.08% | - | - | - | - | - |
EPS (Basic) | 2.33 | 2.55 | 2.08 | 0.72 | 8.81 | 1.85 |
EPS (Diluted) | 2.33 | 2.55 | 2.08 | 0.72 | 8.81 | 1.85 |
EPS Growth | 38.83% | 22.56% | 187.78% | -91.78% | 375.56% | 449.70% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1,303 | 63.55 | -528.49 | 225.2 | 987.26 | 156.43 |
Free Cash Flow Per Share | -15.60 | 0.76 | -6.33 | 2.70 | 11.82 | 1.87 |
Dividend Per Share | 0.750 | 0.750 | 1.000 | 0.750 | - | 0.750 |
Dividend Growth | -25.00% | -25.00% | 33.33% | - | - | - |
Gross Margin | 20.01% | 18.22% | 31.23% | 35.23% | 30.57% | 39.00% |
Operating Margin | 10.68% | 5.81% | 14.24% | 20.04% | 0.84% | 13.36% |
Profit Margin | 5.37% | 5.72% | 5.82% | 2.70% | 40.33% | 8.53% |
Free Cash Flow Margin | -36.00% | 1.70% | -17.67% | 10.05% | 54.15% | 8.63% |
EBITDA | 440.83 | 265.13 | 465.79 | 482.88 | 48.6 | 278.32 |
EBITDA Margin | 12.18% | 7.11% | 15.57% | 21.55% | 2.67% | 15.36% |
D&A For EBITDA | 54.38 | 48.48 | 39.93 | 34.05 | 33.27 | 36.16 |
EBIT | 386.44 | 216.65 | 425.87 | 448.83 | 15.33 | 242.16 |
EBIT Margin | 10.68% | 5.81% | 14.24% | 20.04% | 0.84% | 13.36% |
Effective Tax Rate | 11.34% | 34.48% | 48.64% | 49.50% | - | 13.79% |